A clinical study for people with migraine
June 2020
Alan M Rapoport, MD; Shannon Strom, PhD; Detlef Albrecht, MD; John Kollins (2020) Safety of Dihydroergotamine for the Acute Treatment of Migraine: Reality vs Perception
Presented June 2020 (virtually) at the American Headache Society’s Annual Scientific Meeting
June 2020
Shannon Strom, PhD; John Kollins; Detlef Albrecht, MD (2020) The Efficacy of Dihydroergotamine versus Emerging Acute Migraine Medications
Presented June 2020 (virtually) at the American Headache Society’s Annual Scientific Meeting
May 2020
Shannon Strom, PhD; John Kollins; Detlef Albrecht, MD (2020). Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations
American Academy of Neurology 2020 Annual Meeting
May 2020
Mic Iwashima (2020). Water-insoluble Mucoadhesive Formulation Enables Consistent and Rapid Intranasal Absorption of Drugs, including Granisetron, Zolmitriptan and Dihydroergotamine
American Academy of Neurology 2020 Annual Meeting
January 2020
Detlef Albrecht, MD; Mic Iwashima; Debbie Dillon; Stuart Harris, MD; Jeff Levy, MD (2020). A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
Headache 2020;0:1-12
September 2019
Strom, S., Kollins, J., Albrecht D. (2019). Comparison of the Pharmacokinetics of STS101, an Intranasal Dry Powder Formulation of Dihydroergotamine, with Other Intranasal, Injectable, and Oral Inhaled DHE Formulations
Presented September 2019 at IHC 2019, the 19th Congress of the International Headache Society.